I FU,

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Christian STAPPER, et al

Examiner:

Not Yet Assigned

Art Unit:

1614

Application No.:

10/788,996

Filed:

February 27, 2004

冈

Title: CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 23, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

	(b)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.						
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113					
		or a	notice of allowance under §1.311, whichever occurs first.					
		(1)	The undersigned attorney certifies that each item of information contained in this					
			Information Disclosure Statement was cited in a communication from a foreign					
			patent office in a counterpart foreign application not more than three months prior					
			to the filing of this statement;					
		(2)	The undersigned attorney certifies that no item of information contained in this					
			Information Disclosure Statement was cited in a communication from a foreign					
			patent office in a counterpart foreign application or, to the knowledge of the					
			undersigned attorney after making reasonable inquiry, was known to any					
			individual designated in §1.56(c) more than three months prior to the filing of this					
			statement; or					
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in					
A copy			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is					
			authorized.					
	y of th	of the International Search Report is also enclosed.						
			Respectfully submitted,					
			William C. Coppola, Reg. No. 41,686					

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. DEAV2003-0082US NP

Please	type a	plus sign	(+) inside	this box	\rightarrow	V
--------	--------	-----------	------------	----------	---------------	---

JUL 2 7 2004

TRADEN

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 Sheet of

Complete if Known					
Application Number	10/788,996				
Filing Date	02-27-2004				
First Named Inventor	STAPPER				
Group Art Unit	1614				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	DEAV2003/0082 - US - NP				

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
						,		
	1			-				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Code ³ Number ⁴ (If known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		EP	1 067 109 A1		TAJIMA et al	01-10-2001			
		EP	1 108 713 A1		TAJIMA et al	06-20-2001			
		EP	1 354 879 A1		TAJIMA et al	10-22-2003		1	
		wo	02/051820 A1		TAJIMA et al	07-04-2002			
		wo	02/16331 A1		BROOKS et al	02-28-2002		$oxed{\bot}$	
						-		+	
i		l							

Examiner	W	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.